MSFT 414.2162 -0.3066% AAPL 228.5 -0.2183% NVDA 146.7395 0.5823% GOOGL 167.89 -4.5971% GOOG 169.5501 -4.3872% AMZN 198.38 -2.2181% META 563.1866 -0.4126% BRK-A 564000.0 1.0181% BRK-B 371.74 0.9998% AVGO 164.04 0.4839% TSLA 340.34 -0.4941% TSM 190.62 1.1998% LLY 748.98 -0.588% V 309.9 0.8166% JPM 244.85 1.6903% UNH 597.49 -0.5012% NVO 102.79 -2.3558% WMT 88.39 1.3879% LVMUY 120.53 -0.9044% XOM 122.0297 1.421%

small-cap

One NASDAQ– Listed Biopharmaceutical Stock at Resistance Levels: Viridian Therapeutics Inc

Sep 16, 2024 | Team Kalkine
One NASDAQ– Listed Biopharmaceutical Stock at Resistance Levels: Viridian Therapeutics Inc

VRDN:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Viridian Therapeutics, Inc. (NASDAQ: VRDN)

Company Overview: Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases.

As per our previous US Daily report published on ‘VRDN’ on 10th Sept 2024, Kalkine provided a ‘Speculative Buy’ stance on the stock at USD 14.19 based on price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis and the stock price has now moved by ~59.05% since then and the price has achieved resistance 1 and resistance 2 level.

Noted below are the details of support and resistance levels provided in our previous report:

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Copyright © 2024 Krish Capital Pty Ltd. All rights reserved.